Baiyang Pharmaceutical announced that revenue for the first half of 2026 was 3.56 billion yuan, down 5.11% year on year; net profit attributable to shareholders of listed companies was 225 million yuan, up 37.72% year on year, and 163 million yuan for the same period in 2025; net profit after deducting non-recurring profit and loss was 221 million yuan, up 24.58% year on year. The company plans to publicly issue H shares and list them on the main board of the Hong Kong Stock Exchange Limited.

Baiyang Pharmaceutical announced that revenue for the first half of 2026 was 3.56 billion yuan, down 5.11% year on year; net profit attributable to shareholders of listed companies was 225 million yuan, up 37.72% year on year, and 163 million yuan for the same period in 2025; net profit after deducting non-recurring profit and loss was 221 million yuan, up 24.58% year on year. The company plans to publicly issue H shares and list them on the main board of the Hong Kong Stock Exchange Limited.